Piper Jaffray Companies reaffirmed their hold rating on shares of AMAG Pharmaceuticals (NASDAQ:AMAG) in a report released on Thursday. They currently have a $15.00 price objective on the specialty pharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. Zacks Investment Research lowered shares of AMAG Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, October 24th. B. Riley initiated coverage on shares of AMAG Pharmaceuticals in a research report on Thursday, December 7th. They set a neutral rating and a $16.00 price target on the stock. ValuEngine raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, January 3rd. Janney Montgomery Scott reaffirmed a hold rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. Finally, Jefferies Group reaffirmed a buy rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a research report on Sunday, November 5th. Twelve investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $21.00.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded up $0.60 during mid-day trading on Thursday, hitting $13.85. 603,856 shares of the stock were exchanged, compared to its average volume of 633,511. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59. The company has a market capitalization of $489.93, a price-to-earnings ratio of -2.28 and a beta of 0.79. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $25.20.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative net margin of 35.35% and a negative return on equity of 0.64%. equities analysts predict that AMAG Pharmaceuticals will post -4.79 EPS for the current year.

Large investors have recently added to or reduced their stakes in the business. Hartford Investment Management Co. acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $186,000. Cubist Systematic Strategies LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $197,000. 361 Capital LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $197,000. Aperio Group LLC acquired a new position in shares of AMAG Pharmaceuticals in the third quarter valued at $198,000. Finally, Municipal Employees Retirement System of Michigan increased its holdings in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock valued at $243,000 after purchasing an additional 4,870 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.watchlistnews.com/amag-pharmaceuticals-amag-hold-rating-reiterated-at-piper-jaffray-companies/1817101.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.